Articles with public access mandates - frank spelemanLearn more
OverallFWONIHEuropean CommissionNHMRCSFIGovernment of SpainDFGBELSPOBMBFAlex's Lemonade StandHHMIWellcomeINSERMCancer Research UKSCLGovernment of ItalyFWFHelmholtzANRAIRC Foundation for Cancer Research in ItalyFNRSCIHRNSFCDFFVillum FoundationOTKATelethonSwedish Research CouncilBBSRCMRCWorldwide Cancer Research, UKFondazione CariploZonMwKNAWKWFUK Research & InnovationLymphoma Research Foundation, USAV Foundation, USADamon Runyon Cancer Research FoundationRoyal Society UKMedical Research Future Fund, Australia
Not available anywhere: 18
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
JJ Molenaar, R Domingo-Fernández, ME Ebus, S Lindner, J Koster, ...
Nature genetics 44 (11), 1199-1206, 2012
Mandates: US National Institutes of Health, Science Foundation Ireland
Mutational dynamics between primary and relapse neuroblastomas
A Schramm, J Köster, Y Assenov, K Althoff, M Peifer, E Mahlow, ...
Nature genetics 47 (8), 872-877, 2015
Mandates: German Research Foundation
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
S De Brouwer, K De Preter, C Kumps, P Zabrocki, M Porcu, ...
Clinical cancer research 16 (17), 4353-4362, 2010
Mandates: Research Foundation (Flanders)
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice
LC Heukamp, T Thor, A Schramm, K De Preter, C Kumps, B De Wilde, ...
Science translational medicine 4 (141), 141ra91-141ra91, 2012
Mandates: Research Foundation (Flanders), German Research Foundation
Challenges for CNV interpretation in clinical molecular karyotyping: lessons learned from a 1001 sample experience
K Buysse, B Delle Chiaie, R Van Coster, B Loeys, A De Paepe, G Mortier, ...
European journal of medical genetics 52 (6), 398-403, 2009
Mandates: Research Foundation (Flanders)
MiR‐137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A
K Althoff, A Beckers, A Odersky, P Mestdagh, J Köster, IM Bray, K Bryan, ...
International journal of cancer 133 (5), 1064-1073, 2013
Mandates: US National Institutes of Health, Science Foundation Ireland
Revised risk estimation and treatment stratification of low-and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers
A Oberthuer, D Juraeva, B Hero, R Volland, C Sterz, R Schmidt, A Faldum, ...
Clinical Cancer Research 21 (8), 1904-1915, 2015
Mandates: Government of Spain
Comparison of miRNA profiles of microdissected Hodgkin/Reed‐Sternberg cells and Hodgkin cell lines versus CD77+ B‐cells reveals a distinct subset of …
P Van Vlierberghe, AN De Weer, P Mestdagh, T Feys, K De Preter, ...
British journal of haematology 147 (5), 686-690, 2009
Mandates: Research Foundation (Flanders)
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
T Van Maerken, A Rihani, A Van Goethem, A De Paepe, F Speleman, ...
Cancer letters 344 (2), 157-165, 2014
Mandates: Research Foundation (Flanders)
Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia
A Wallaert, K Durinck, W Van Loocke, I Van de Walle, F Matthijssens, ...
Leukemia 30 (9), 1927-1930, 2016
Mandates: Research Foundation (Flanders)
Neuroblastoma genetics and phenotype: a tale of heterogeneity
F Speleman, K De Preter, J Vandesompele
Seminars in cancer biology 21 (4), 238-244, 2011
Mandates: Research Foundation (Flanders)
The epigenetic landscape of T-cell acute lymphoblastic leukemia
J Van der Meulen, N Van Roy, P Van Vlierberghe, F Speleman
The international journal of biochemistry & cell biology 53, 547-557, 2014
Mandates: Research Foundation (Flanders)
ALK positively regulates MYCN activity through repression of HBP1 expression
S Claeys, G Denecker, K Durinck, B Decaesteker, LM Mus, S Loontiens, ...
Oncogene 38 (15), 2690-2705, 2019
Mandates: Research Foundation (Flanders), Belgian Science Policy Office
High‐risk clonal evolution in chronic B‐lymphocytic leukemia: single‐center interphase fluorescence in situ hybridization study and review of the literature
A Janssens, N Van Roy, B Poppe, L Noens, J Philippé, F Speleman, ...
European Journal of Haematology 89 (1), 72-80, 2012
Mandates: Research Foundation (Flanders)
Long non-coding RNAs in leukemia: biology and clinical impact
T Lammens, K Durinck, A Wallaert, F Speleman, P Van Vlierberghe
Current opinion in hematology 24 (4), 353-358, 2017
Mandates: Research Foundation (Flanders)
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma
A Rihani, T Van Maerken, B De Wilde, F Zeka, G Laureys, K Norga, ...
Pediatric blood & cancer 61 (10), 1867-1870, 2014
Mandates: Research Foundation (Flanders), Government of Spain
Low-cost dedicated mini-arrays for high-throughput analysis of DNA copy-number alterations in neuroblastoma
K De Preter, B Menten, S De Brouwer, C Kumps, E Michels, N Van Roy, ...
Cancer letters 269 (1), 111-116, 2008
Mandates: Research Foundation (Flanders)
Neuroblastoma Epigenetic Landscape: Drugging Opportunities
V Veschi, K Durinck, CJ Thiele, F Speleman
Neuroblastoma: Discoveries and Challenges, 71-95, 2024
Mandates: European Commission
Available somewhere: 165
Identification of ALK as a major familial neuroblastoma predisposition gene
YP Mossé, M Laudenslager, L Longo, KA Cole, A Wood, EF Attiyeh, ...
Nature 455 (7215), 930-935, 2008
Mandates: US National Institutes of Health
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
L Ma, J Young, H Prabhala, E Pan, P Mestdagh, D Muth, ...
Nature cell biology 12 (3), 247-256, 2010
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Publication and funding information is determined automatically by a computer program